PharmaJet said today it inked a global license agreement with South Korean bioptherapeutics company Genexine to develop and commercialize DNA vaccines using PharmaJet’s needle-free injection system.
Through the deal, Genexine will gain access to use both the PharmaJet Stratis and Tropis devices for their Phase I and Phase IIa human clinical studies. The deal also includes a provision for a possible expansion into Phase III clinical trials and commercialization.
Genexine’s product pipeline includes a vaccine for human papilloma virus type 16 and type 18 and associated cervical intraepithelial neoplasia which eventually causes cervical cancer.
“We are pleased to be part of the upcoming clinical trials of these DNA vaccines. Our needle-free technology features a precise and consistent method of delivery, which helps to maximize target gene expression in the human body. In addition, it offers benefits over the alternative of electroporation delivery,” PharmaJet chair & CEO Ron Lowy said in a press release.
Last month, PharmaJet released results from a study evaluating its needle-free injection technology as a way to administer the poliovirus vaccine.
